The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis - GBI Research Reports

The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis - GBI Research Reports
The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
Published Dec 01, 2009
186 pages — Published Dec 01, 2009
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

SummaryGBI Research, the leading business intelligence provider, has released its latest research 'The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis.' The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global oncology therapeutics market. The report analyzes the markets for oncology therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.ScopeThe scope of this report includes:- Annualized market data for the oncology therapeutics market from 2000 to 2008, forecast forward to 2015- Analysis of the leading therapeutic segments including lung cancer, breast cancer, prostate cancer, colorectal cancer and Non-Hodgkin's Lymphoma.- Analysis of the oncology diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan - Market characterization of the oncology therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns - Key drivers and barriers that have a significant impact on the market - Coverage of pipeline molecules in various phases of drug development - Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, Novartis AG, Sanofi-aventis, Amgen, AstraZeneca, Merck & Co, Pfizer Inc, Celgene Corporation, Bristol-Myers Squibb and Eli Lilly- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global oncology therapeutics marketReasons to buyThe report will enhance your decision making capability. It will allow you to- Align product portfolio to the markets with high growth potential- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth - Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety- Develop key strategic initiatives by understanding key focus areas of leading companies - Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

  
Source:
Document ID
GBIHC002MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents49
1.1 List of Tables82
1.2 List of Figures103
2 Global Oncology Therapeutics Market: Introduction132
2.1 GBI Research Report Guidance141
3 Global Oncology Therapeutics Market: Cancer Epidemiology151
4 Global Oncology Therapeutics Market: Market Overview1615
4.1 Introduction162
4.2 Revenue Forecasts for the Global Oncology Therapeutics Market181
Sales Value181
4.2.2 Sales Volume191
4.2.3 Drug Prices201
4.2.4 Treatment Usage Patterns211
4.2.4.1 Diseased Population221
4.2.4.2 Treatment Seeking Population231
4.2.4.3 Diagnosis Population231
4.2.4.4 Prescription Population241
4.3 Generics in Oncology Therapeutics Market251
4.4 Oncology therapeutics market Drivers261
4.4.1 Steady Increase in the Ageing Population261
4.4.2 New Innovative Products in the Pipeline271
4.4.3 Rapid Uptake of Targeted Therapies in Key Cancer Indications271
4.5 Oncology Therapeutics Market Restraints271
4.5.1 The US Cancer Incidence Moving Towards a Decelerating Growth Rate 271
Patent Expirations and Entry of Generics Pose as a Severe Threat for Primary Manufacturers281
4.5.3 Restrictive Pricing and Reimbursement Policies Causing Serious Problems in the Oncology Therapeutics Market Growth 291
4.5.4 More Than 80 Molecules to be Launched Over the Next Seven years - Leading to More Competition301
5 Global Oncology Therapeutics Market: Pricing and Reimbursement3110
5.1 Average Cost of Drug Treatment312
5.2 The US331
5.2.1 Pricing331
5.2.2 Medicare Reimbursement on Cancer Drugs331
5.3 Europe342
5.3.1 Pricing and Reimbursement - Country Analysis361
5.3.1.1 United Kingdom361
5.3.1.2 Germany 371
5.3.1.3 France 381
5.3.1.4 Italy 381
5.3.1.5 Spain 392
6 Global Oncology Therapeutics Market: Geographical Landscape4124
6.1 Geographic Break-up411
6.2 The US421
6.2.1 Sales Value421
6.2.2 Sales Volume431
6.2.3 Drug Prices441
6.2.4 Treatment Usage Patterns451
6.2.4.1 Diseased Population461
6.2.4.2 Treatment Seeking Population471
6.2.4.3 Diagnosis Population481
6.2.4.4 Prescription Population481
6.3 Top Five European Countries491
6.3.1 Sales Value492
6.3.2 Sales Volume511
6.3.3 Drug Prices512
6.3.4 Treatment Usage Patterns531
6.3.4.1 Diseased Population541
6.3.4.2 Treatment Seeking Population541
6.3.4.3 Diagnosis Population551
6.3.4.4 Prescription Population561
6.4 Japan571
6.4.1 Sales Value571
6.4.2 Sales Volume581
6.4.3 Drug Prices591
6.4.4 Treatment Usage Patterns601
6.4.4.1 Diseased Population611
6.4.4.2 Treatment Seeking Population621
6.4.4.3 Diagnosis Population631
6.4.4.4 Prescription Population632
7 Global Oncology Therapeutics Market: Therapeutic Landscape 6550
7.1 Breast Cancer Therapeutics Market651
7.1.1 Introduction651
7.1.1.1 Symptoms661
7.1.1.2 Treatment671
7.1.1.3 Epidemiology671
7.1.2 Sales Value671
7.1.3 Sales Volume681
7.1.4 Drug Prices691
7.1.5 Treatment Usage Patterns702
7.1.5.1 Diseased Population721
7.1.5.2 Treatment Seeking Population721
7.1.5.3 Diagnosis Population731
7.1.5.4 Prescription Population741
7.2 Non-Hodgkin s Lymphoma Therapeutics Market751
7.2.1 Introduction751
7.2.1.1 Symptoms751
7.2.1.2 Treatment751
7.2.1.3 Epidemiology761
7.2.2 Sales Value762
7.2.3 Sales Volume781
7.2.4 Drug Prices781
7.2.5 Treatment Usage Patterns792
7.2.5.1 Diseased Population811
7.2.5.2 Treatment Seeking Population811
7.2.5.3 Diagnosis Population821
7.2.5.4 Prescription Population831
7.3 Colorectal Cancer Therapeutics Market831
7.3.1 Introduction832
7.3.1.1 Symptoms851
7.3.1.2 Treatment851
7.3.1.3 Epidemiology861
Sales Value871
7.3.3 Sales Volume881
Drug Prices891
7.3.5 Treatment Usage Patterns901
7.3.5.1 Diseased Population911
7.3.5.2 Treatment Seeking Population921
7.3.5.3 Diagnosis Population921
7.3.5.4 Prescription Population931
7.4 Prostate Cancer Therapeutics Market941
7.4.1 Introduction941
7.4.1.1 Symptoms951
7.4.1.2 Treatment951
7.4.1.3 Epidemiology961
7.4.2 Sales Value961
7.4.3 Sales Volume971
7.4.4 Drug Prices981
7.4.5 Treatment Usage Patterns991
7.4.5.1 Diseased Population1001
7.4.5.2 Treatment Seeking Population1011
7.4.5.3 Diagnosis Population1021
7.4.5.4 Prescription Population1021
7.5 Lung Cancer Therapeutics Market1031
7.5.1 Introduction1031
7.5.1.1 Symptoms1041
7.5.1.2 Treatment1051
7.5.1.3 Epidemiology1061
7.5.2 Sales Value1071
7.5.3 Sales Volume1081
Drug Prices1091
7.5.5 Treatment Usage Patterns1092
7.5.5.1 Diseased Population1111
7.5.5.2 Treatment Seeking Population1121
7.5.5.3 Diagnosis Population1131
7.5.5.4 Prescription Population1141
8 Global Oncology Therapeutics Market: Pipeline Analysis11519
Introduction1151
8.1.1 R&D Strategies1161
8.2 R&D Trends1171
8.2.1 Discovery of Unknown Mutations that Play Key Role in Cancers1171
8.2.1.1 UTX The Key for Many Multiple Myeloma and Esophageal Cancer Cases1171
8.2.1.2 Synthetic Lethality A New Mechanism of Cell Death1171
8.2.1.3 Matrix Metalloproteinase 8 (MMP 8) Stimulation1181
8.2.2 Pairing Therapeutics and Diagnostics1181
8.3 Profiles of Key Late-Stage Drugs1191
8.3.1 Angiogenesis and Multi-Targeted Kinase Inhibitors 1191
8.3.1.1 Zactima1191
8.3.1.2 Pazopanib1201
8.3.1.3 Axitinib1201
8.3.2 Hsp90 Inhibitors1211
8.3.2.1 IPI-5041211
8.3.2.2 KOS-9531221
8.3.3 Insulin-like Growth Factor Receptor Inhibitors1221
8.3.3.1 CP-751,871(figitumumab)1221
8.3.3.2 MK-06461231
8.3.3.3 CB76301231
8.3.4 Hedgehog Inhibitors1241
GDC-04991241
8.3.5 Immuno-conjugates1241
8.3.5.1 SGN-351241
8.3.5.2 Trastuzumab-DM1 (T-DM1)1241
8.3.5.3 CMC5441251
8.4 Insights into Most Promising Drugs1251
8.4.1 Provenge1251
8.4.1.1 Introduction1251
8.4.1.2 Mechanism of Action1251
8.4.1.3 Clinical Trial Management1252
8.4.1.4 Follow-on Indications1271
8.4.1.5 Market Potential1271
8.4.2 Denosumab1271
8.4.2.1 Introduction1271
8.4.2.2 Mechanism of Action1271
8.4.2.3 Clinical Trial Management1281
Market Potential1291
8.4.3 Tasigna1291
8.4.3.1 Introduction1291
8.4.3.2 Mechanism of Action1291
8.4.3.3 Clinical Trial Management1291
8.4.3.4 Market Potential1301
8.4.4 Aflibercept1301
8.4.4.1 Introduction1301
8.4.4.2 Mechanism of Action1301
8.4.4.3 Clinical Trial Management1311
8.4.4.4 Market Potential1311
8.4.5 Tykerb1311
8.4.5.1 Introduction1311
8.4.5.2 Mechanism of Action1311
8.4.5.3 Clinical Trial Management1321
8.4.5.4 Market Potential1331
9 Global Oncology Therapeutics Market: Competitive Landscape13436
9.1 Evolving competitive landscape1341
9.1.1 Major players1351
9.1.2 Key areas focused for R&D1351
9.1.3 Challenges faced by brands in marketing the oncology products1362
9.2 Market Share Analysis1381
9.2.1 Rituxan, Avastin, Revlimid and Herceptin are expected to lead the market through 20151392
9.3 Roche/Genentech1411
9.3.1 Key Oncology Drugs1421
9.3.1.1 Rituxan1421
9.3.1.2 Avastin1431
9.3.1.3 Herceptin1431
9.3.1.4 Tarceva1441
9.3.1.5 Xeloda1441
9.3.2 Key Indications of Interest1451
9.3.3 Pipeline Analysis1462
9.3.4 Key Strategies1481
9.3.4.1 The Next Drug Generation: Small Molecule Conjugates1481
9.3.4.2 Targeted Gene Silencing to Discover Drugs Which can Cure Cancer1481
9.3.4.3 Mergers and Acquisitions An Excellent Strategy to Stay Competitive in the Market1481
9.4 Novartis1481
9.4.1 Key Oncology Drugs1491
9.4.1.1 Gleevec1491
9.4.1.2 Zometa1501
9.4.1.3 Femara1501
9.4.1.4 Sandostatin1511
9.4.1.5 Exjade1511
9.4.1.6 Tasigna1511
9.4.2 Key Indications of Interest1521
9.4.3 Pipeline Analysis1521
9.4.4 Key Strategies1531
9.4.4.1 Translational Science to Explore Multiple Disease Indications of Pipeline Drugs1531
9.4.4.2 The Strategy of Drug Combinations Going to Play a Significant Role in Development Programs 1531
9.4.4.3 Biomarkers Development to Evaluate Safety and Efficacy of Pipeline Drugs1541
9.4.4.4 Introducing Diagnostic Tests, Programs and Materials as a Package to Enhance Patient Adherence1541
9.4.4.5 Maximizing Affordability and Sustainability of Drugs to Broader Group of Patients1541
9.4.4.6 Focused Strategy for Drug Development1541
9.4.4.7 Functional Genomics to Develop Breakthrough Technologies in Cancer Cure1551
9.5 Sanofi-Aventis1551
9.5.1 Key Oncology Drugs1561
9.5.1.1 Taxotere1561
9.5.1.2 Eloxatin1571
9.5.2 Key Indications of Interest1571
9.5.3 Pipeline Analysis1581
9.5.4 Key Strategies1591
9.6 Amgen1601
9.6.1 Key Oncology Drugs1611
9.6.1.1 Neulasta1611
9.6.1.2 Neupogen1621
9.6.1.3 Vectibix1621
9.6.1.4 Denosumab1621
9.6.2 Key of Indications of Interests1631
9.6.3 Pipeline Analysis1632
9.6.4 Key Strategies1651
9.6.4.1 Replacement Value on Declining Drug Revenues1651
Continuance of its Own Old Strategies1651
9.6.4.3 Reorientation of Research and Development Focus to Maximize Probability of Blockbuster drugs1651
9.7 Astra Zeneca1651
9.7.1 Key Oncology Drugs1661
9.7.1.1 Arimidex 1661
9.7.1.2 Casodex 1661
9.7.1.3 Iressa 1671

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis" Dec 01, 2009. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/The-Future-of-Oncology-Therapeutics-Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis-2115-5>
  
APA:
GBI Research Reports. (2009). The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis Dec 01, 2009. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/The-Future-of-Oncology-Therapeutics-Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis-2115-5>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.